GoalVest Advisory LLC Has $56,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

GoalVest Advisory LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 31.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 846 shares of the medical research company’s stock after purchasing an additional 201 shares during the quarter. GoalVest Advisory LLC’s holdings in Edwards Lifesciences were worth $56,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the 1st quarter worth about $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $29,000. Webster Bank N. A. purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $39,000. Peoples Bank KS purchased a new stake in Edwards Lifesciences in the 3rd quarter worth about $40,000. Finally, Versant Capital Management Inc lifted its stake in Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock valued at $2,744,438 over the last three months. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 2.4 %

EW stock opened at $67.76 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business has a fifty day moving average of $67.44 and a 200-day moving average of $76.18. The company has a market cap of $39.96 billion, a P/E ratio of 9.78, a PEG ratio of 3.81 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on EW. Wells Fargo & Company reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. UBS Group cut their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Daiwa Capital Markets raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Stifel Nicolaus cut their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research note on Thursday, July 25th. Finally, Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.